指南与共识肝病

AASLD与AGA原发性胆汁性胆管炎管理临床实践指南

AASLD AGA clinical Practice Guideline on management of primary biliary cholangitis.
指南 / 共识 · Hepatology · 2026-10-22

该指南由美国胃肠病学会(AGA)与美国肝病研究学会(AASLD)联合制定,针对成人原发性胆汁性胆管炎(PBC)的六个优先临床问题完成系统评价,并基于GRADE框架形成六条推荐,涵盖抗线粒体抗体阴性疑似PBC的PBC特异性抗核抗体检测、熊去氧胆酸(UDCA)一线治疗、肝硬度测定预后评估、PPAR激动剂用于UDCA应答不佳或不耐受者、linerixibat治疗中重度瘙痒及肝移植后UDCA预防复发,证据确定性为中至极低。

要点

  • 推荐UDCA作为PBC一线治疗,并关注应答评估与风险分层。
  • 抗线粒体抗体阴性疑似PBC可检测PBC特异性抗核抗体辅助诊断。
  • UDCA应答不佳或不耐受者可考虑PPAR激动剂,中重度瘙痒可用linerixibat。

核心结论

  • 指南强调早期诊断、优化一线治疗、基于风险的治疗升级、症状管理及预防肝移植后疾病复发,以改善患者结局与生活质量。

研究设计与样本

  • AGA与AASLD召集多学科专家组,针对6个优先临床问题开展系统评价,采用GRADE框架及证据到决策框架制定成人PBC临床实践推荐。

主要发现

  • 专家组就6个临床问题达成6条推荐,证据确定性范围为中等至极低。

关键数值与推荐

  • 推荐涉及抗线粒体抗体阴性疑似PBC使用PBC特异性抗核抗体、UDCA作为一线治疗、肝硬度测定用于预后评估。
  • 推荐涉及UDCA应答不佳或不耐受者使用过氧化物酶体增殖物激活受体激动剂、linerixibat用于中重度瘙痒、肝移植后UDCA预防疾病复发。

临床怎么用

  • 临床可依据指南推荐对PBC进行早期诊断、UDCA一线治疗及应答评估,并根据风险分层考虑治疗升级和症状管理。

局限性

  • 证据确定性范围为中等至极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AIMS: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with progressive fibrosis, cirrhosis, liver transplantation, and premature mortality. Despite effective therapies, important challenges remain in the diagnosis and management of PBC, including identification of antimitochondrial antibody-negative disease, assessment of response to ursodeoxycholic acid (UDCA), risk stratification, treatment of patients with inadequate response, management of cholestatic pruritus, and prevention of recurrent disease after liver transplantation. The aim of this guideline was to develop evidence-based recommendations addressing these key areas of clinical care. METHODS: The American Gastroenterological Association (AGA) and the American Association for the Study of Liver Diseases (AASLD) convened a multidisciplinary panel to develop clinical practice recommendations for adults with PBC. Systematic reviews were performed for 6 prioritized clinical questions. The Grading of Recommendations Assessment, Development and Evaluation framework was used to prioritize clinical outcomes and assess evidence, and its Evidence to Decision Framework was used to develop recommendations. RESULTS: The guideline panel agreed on 6 recommendations. These recommendations address the use of PBC-specific antinuclear antibodies in antimitochondrial antibody-negative suspected PBC, UDCA as first-line therapy, liver stiffness measurement for prognostication, peroxisome proliferator-activated receptor agonists for patients with inadequate response or intolerance to UDCA, linerixibat for moderate to severe pruritus, and UDCA prophylaxis post-transplantation to reduce disease recurrence. The certainty of evidence ranged from moderate to very low. CONCLUSIONS: The guideline emphasizes early diagnosis, optimization of first-line therapy, risk-based treatment escalation, symptom management, and prevention of post-transplantation disease recurrence to improve patient outcomes and quality of life.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Levy C, Mayo MJ, Carey EJ, et al. AASLD AGA clinical Practice Guideline on management of primary biliary cholangitis. Hepatology. 2026. PMID: 42910434. doi:10.1097/HEP.0000000000001875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。